I am a
Home I AM A Search Login

Papers of the Week


Papers: 7 May 2022 - 13 May 2022

PAIN TYPE:
Migraine/Headache


2022 May 06


Headache

Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.

Abstract

To develop a multivariable model assessing factors predicting a second-dose response to eptinezumab treatment over weeks 13-24 in patients with migraine initially reporting a suboptimal response over weeks 1-12.